Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies (PACIFIC)

Overview

Información sobre este estudio

The primary objective of this study is to investigate the safety, tolerability, and effectiveness of multiple doses of LP352 in adult subjects with developmental and epileptic encephalopathies.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Key Inclusion Criteria:

1. Male or non-pregnant, non-lactating female, age 12 to 65 years

2. Diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and
epileptic encephalopathy

3. Has a minimum number of seizures per 4-week period while taking 1 to 4 anti-seizure
medications

4. All medications and epilepsy interventions must be stable for 4 weeks before screening
and are expected to remain stable during the study

5. The patient/parent/caregiver is able and willing to attend study visits, complete the
diary and take study drug as instructed

Key Exclusion Criteria:

1. Current or past history of cardiovascular or cerebrovascular disease, such as cardiac
valvulopathy, myocardial infarction, stroke, pulmonary arterial hypertension or
abnormal blood pressure

2. Has glaucoma, renal impairment, liver disease or any other medical condition that
would affect study participation or pose a risk to the subject

3. Current or recent history of moderate or severe depression, anorexia nervosa, bulimia
or at risk of suicidal behavior

4. Currently taking anorectic agents, monoamine oxidase inhibitors; serotonin agonists or
antagonists including fenfluramine, atomoxetine, vortioxetine, or other medications
for weight loss

5. Positive test result on the drug screen, except tetrahydrocannabinol (THC) for
patients taking prescribed cannabidiol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 1/10/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

David Burkholder, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20538965

Mayo Clinic Footer